Fibrosis (Cirrhosis)

Subscribe to Selected New Research on Fibrosis

32451 relevant articles (1462 outcomes, 3297 trials/studies) found for this Disease

Description: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.

Also Known As:

Cirrhosis; Fibroses

Relationship Network

Disease Context: Research Results

Signs and Symptoms Pathological Conditions

Pathologic Processes: 2442

Fibrosis: 32451

Cicatrix: 12996

Retroperitoneal Fibrosis: 365

Nephrogenic Fibrosing Dermopathy: 282

Related Diseases

1.	Inflammation
2.	Fibrosis (Cirrhosis)
3.	Hepatocellular Carcinoma (Hepatoma)
4.	Hemorrhage
5.	Ascites

Experts

1.	Arroyo, Vicente: 20 articles (05/2008 - 01/2002)
2.	Ginès, Pere: 15 articles (09/2008 - 04/2003)
3.	Jiménez, Wladimiro: 12 articles (02/2008 - 02/2002)
4.	Such, José: 11 articles (07/2008 - 07/2002)
5.	Francés, Rubén: 11 articles (07/2008 - 07/2002)
6.	Rodés, Juan: 11 articles (05/2008 - 01/2002)
7.	Bosch, Jaime: 11 articles (05/2008 - 12/2002)
8.	Møller, S: 11 articles (01/2007 - 01/2000)
9.	Henriksen, J H: 11 articles (01/2007 - 01/2000)
10.	Nicholson, M L: 11 articles (01/2005 - 02/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Fibrosis:

1.	CollagenIBA 04/01/2009 - "More importantly, these changes in gene expression were associated with marked attenuation of lung fibrosis, including decreased collagen deposition and improved lung function and survival. " 01/01/1999 - "Finally, the observation that culture of RPT cells on a reconstituted basement membrane preparation results in a significant reduction in total collagen production and alterations in the molecular forms of type IV and type I molecules synthesized indicates that integrity of the tubular basement membrane may represent an important component in preventing the development of tubulointerstitial fibrosis." 01/01/2009 - "RESULTS: Compared to the control-treatment animals on day 28, real-time PCR, Western blot, and confocal microscopy revealed that Smad7 gene transfer significantly attenuated the increased peritoneal fibrosis including the thickening of fibrotic peritoneum, accumulation of alpha-SMA and collagen I, and an improvement in peritoneal dysfunction (all p < 0.05). " 05/01/2003 - "The severity of renal fibrosis, based on the measurement of total collagen (13.5 +/- 1.5 versus 9.8 +/- 1.0 microg/mg kidney on day 14; -/- versus +/+) and interstitial area stained by Masson trichrome (22 +/- 4% versus 14 +/- 3% on day 14; -/- versus +/+) was significantly greater in the uPAR-/- mice. " 02/01/2006 - "Concomitantly, this treatment resulted in an improvement in mucus secretion and subepithelial fibrosis in the chronically asthmatic mice, with a quantitatively measured reduction in lung collagen, a prominent feature of airway remodeling. " Order ALL the reference details at left...
2.	InterferonsIBA 01/01/1999 - "This overview provides evidence that interferon in patients who have not cleared hepatitis C virus (HCV) significantly reduces viral load, serum ALT activity, improves histological activity and blocks progression of fibrosis compared to the natural history of the disease. " 10/01/2004 - "In contrast, protection against hepatic fibrosis is dependent on interferon (IFN)-gamma and is controlled by a major genetic locus that is located on 6q23, near the gene encoding the IFN-gamma receptor beta chain. " 04/01/2000 - "Histological examination 12 months after interferon was completed demonstrated that hepatic fibrosis improved in sustained responders and was unchanged in transient and non-responders, but progressed in untreated patients. " 09/01/1997 - "The efficacy of interferon in patients with decompensated cirrhosis is not well documented and its use cannot be recommended. " 09/01/1999 - "Is interferon a useful treatment for virus C cirrhosis?" Order ALL the reference details at left...
3.	Lamivudine (3TC)FDA Link 12/01/2002 - "BACKGROUND/AIMS: Although several clinical trials have suggested that lamivudine treatment can be very effective in patients with decompensated HBV-associated cirrhosis, its role and clinical efficacy are still uncertain because of the study designs. " 04/01/2007 - "It has been statistically proven that the efficacy of lamivudine therapy correlates with degree of fibrosis and higher histological activity index values. " 09/01/2003 - "CONCLUSION: Significant improvement in liver histology, both necroinflammation and fibrosis, can be obtained in the majority of patients treated with lamivudine for one year." 01/01/2003 - "One-year of Lamivudine treatment significantly improved necroinflammation and reduced the progression of fibrosis and the histologic activity index. " 07/01/2000 - "BACKGROUND & AIMS: One-year lamivudine therapy significantly suppressed hepatitis B virus (HBV) replication, improved hepatic necroinflammatory activity, and prevented progression of fibrosis. " Order ALL the reference details at left...
4.	Transforming Growth Factor beta (TGF-beta)IBA 12/01/1993 - "The density of the antimacrophage (M phi) antibody positive cells in the muscular layers was apparently greater in the remarkable fibrosis group than in the unremarkable fibrosis group, and the density of the anti-TGF-beta antibody positive cells in the remarkable fibrosis group was significantly greater than in the unremarkable fibrosis group. " 02/01/2006 - "While high levels of TGF-beta appeared to be associated with protection against fibrosis, the strength of the association was low." 05/01/1988 - "These findings suggest that TGF-beta secreted in an inflammatory site may be beneficial in diminishing lymphocyte function while promoting fibrosis and tissue repair. " 06/01/2009 - "EMT antagonists, TGF-beta signal modulator, and HIF-1alpha inhibitor could be useful for the treatment of fibrosis." 04/01/2003 - "Because TGF-beta is central to the progression of fibrosis, selective inhibition of this signaling pathway could provide a novel treatment in many fibrotic diseases. " Order ALL the reference details at left...
5.	Bleomycin (Blenoxane)FDA LinkGeneric 01/01/2009 - "Concomitantly, we observed a clear decrease in neutrophil infiltration and a significant reduction in the severity of bleomycin-induced lung fibrosis in mice treated with placenta-derived cells, irrespective of the source (allogeneic or xenogeneic) or delivery route. " 02/01/2005 - "The therapeutic efficacy of the bleomycins is limited by development of lung fibrosis. " 08/15/1989 - "Bleomycin (BLEO), an antitumor antibiotic effective against a variety of malignancies, has been associated classically with a pulmonary toxic reaction producing diffuse interstitial fibrosis. " 04/01/2007 - "CONCLUSION: LLDT-8 showed protective effects against bleomycin-induced lung fibrosis, and the results suggested the potential role of LLDT-8 in the treatment of this disease." 09/01/2005 - "Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis." Order ALL the reference details at left...
6.	Transforming Growth Factor beta1 (TGF beta 1)IBA 06/01/2006 - "Significantly greater fibrosis and TGF-beta1 expression were found in mdx from the 6th week. " 08/01/2002 - "It also improved significantly histological changes of fibrosis and decreased the expression of alpha-SMA and TGF-beta1 in liver of these rats (P<0.05 or P<0.01). " 04/01/1999 - "The neutralization of TGF-beta1 has been beneficial in the reduction of fibrosis. " 10/01/2008 - "Despite the impressive results obtained in experimental renal fibrosis, TGF-beta1 blockade has not yet translated into an effective and safe therapeutic in human patients. " 01/01/2006 - "Its therapeutic effect could be related to a down-regulation of TGF-beta1 as proved in a well characterized pig model of radiation induced fibrosis, where the efficacy of Cu-Zn SOD has been shown in reversing fibrosis. " Order ALL the reference details at left...
7.	Hepatitis B e AntigensIBA 07/01/2003 - "Multivariate analysis showed that difference in HBV genotype influenced significantly either the clearance of HBeAg or the development of cirrhosis. " 09/01/2007 - "The rate of fibrosis progression was lower in patients with sustained disease remission than in those who remained HBeAg positive (median 0 fibrosis units/year, range -2.00 to -0.70 fibrosis units/year, versus median 0.51 fibrosis units/year, range 0 to +2.03 fibrosis units/year, P = 0.02). " 07/01/2003 - "In conclusion, HBeAg was cleared from sera more frequently and earlier in patients with genotype B compared with those with genotype C, and development of cirrhosis occurred less frequently in patients with genotype B compared with those with genotype C. " 08/01/2007 - "CONCLUSION: PEG-IFN is effective and safe for HBeAg-positive patients with advanced fibrosis. " 01/01/1999 - "Both HBeAg and anti-HBe positive patients are benefited, as may be patients with cirrhosis." Order ALL the reference details at left...
8.	Messenger RNA (mRNA)IBA 10/01/2008 - "Moreover, it dramatically reduced hepatic inflammatory changes and fibrosis concomitantly with marked reductions in the mRNA levels for inflammatory cytokine, chemokine, and profibrogenic genes. " 08/01/2008 - "In acute study using a single drug injection, we observed a rapid transient increase of ALT and mRNA levels of KLF5 followed by increases in fibrosis-related genes. " 12/01/2005 - "METHODS: We used real-time quantitative RT PCR to study the messenger RNA expression of 240 selected genes in 2 pools of liver specimens according to the stages of fibrosis (Metavir score; mild fibrosis = F1 and septal fibrosis = F2). " 01/01/2002 - "The purpose of the present study was to assess the correlation that likely exists among increased portal pressure (Pp), portal blood flow quantity (Qp) and ETA and ETB receptor mRNA expression in human cirrhosis. " 01/01/2000 - "PDGF-B mRNA increase up to day 15, marking the onset of fibrosis, and decreases thereafter, whereas the expression of the PDGF-Rbeta mRNA remains elevated more than threefold over the entire study period. " Order ALL the reference details at left...
9.	Ribavirin (Virazole)FDA LinkGeneric 12/01/2006 - "Thus, (1) patients with genotypes 2 and 3 and severe fibrosis can be treated with low dose of Peg-IFN and ribavirin, (2) this study suggests that patients with genotypes 1, 4 and 5 and high viraemia could receive a standard dose of Peg-IFN associated with ribavirin for 48 weeks, (3) side effects limit the efficacy of the treatment with standard dose of Peg-IFN in patients with genotypes 1, 4 and 5 and low viraemia, (4) more studies are needed for patients with genotype 2 or 3 to define the optimal duration (24 or 48 weeks) in patients with severe fibrosis." 01/01/2008 - "Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis." 04/01/2000 - "Although current evidence suggests that the combination of ribavirin and IFN-alpha might be more efficacious than IFN alone in increasing the response rate in patients in the advanced fibrotic stage, the efficacy of this regimen for patients with well-compensated HCV-related cirrhosis is still unknown and prospective well-designed studies are urgently needed. " 03/01/2005 - "A recent clinical trial of peginterferon alpha-2a plus ribavirin in African American patients resulted in a higher SVR rate, 26%, than observed previously, and 90% of patients showed stabilization or improvement in fibrosis. " 01/01/2008 - "CONCLUSIONS: PEG-IFN-alpha2b plus ribavirin for 48 weeks is an efficacious and well-tolerated treatment regimen for patients with HCV-induced cirrhosis. " Order ALL the reference details at left...
10.	Colchicine FDA LinkGeneric 11/15/2000 - "In summary, colchicine has only weak antioxidant properties, but does afford some protection against oxidative stress; more importantly, long term treatment with this drug may be of value in producing regression of established cirrhosis." 05/01/1997 - "Colchicine is effective in decreasing hepatic fibrosis. " 01/01/1989 - "Colchicine, too, has been reported to improve survival in patients with established cirrhosis. " 04/01/2005 - "BACKGROUND & AIMS: Colchicine improved survival and reversed cirrhosis in several small clinical trials. " 04/01/2005 - "Liver histology improves to septal fibrosis in a minority of patients after 24 months of treatment, with similar rates of improvement in patients receiving placebo and colchicine. " Order ALL the reference details at left...

Therapies and Procedures

1.	Liver Transplantation 01/01/2007 - "Liver transplantation provides the best cure for both the HCC and the underlying cirrhosis. " 07/01/2005 - "Percutaneous ablation is considered the best treatment option for patients with Child-Pugh class A or B cirrhosis and a single, nodular-type HCC smaller than 5 cm or as many as three HCC lesions, each smaller than 3 cm, when surgical resection or liver transplantation is not suitable. " 11/01/2004 - "For Child class B and C patients with a small HCC, liver transplantation offers the best results, whereas partial liver resection is indicated in patients with well-compensated cirrhosis. " 09/01/2003 - "The best results of liver transplantation were achieved in patients transplanted on a routine basis with a diagnosis of PBC (91.4%), autoimmunologic cirrhosis (81.1%), postalcoholic cirrhosis (80%), or hemochoromatosis (100%). " 12/01/1997 - "Orthotopic liver transplantation is a highly effective treatment for patients with end-stage cirrhosis. " Order ALL the reference details at left...
2.	Transplantation (Transplant Recipients) 06/01/2009 - "Early free functional muscle transplantation shows best results in patients with direct muscle defect, because all vascular and neuronal structures are still available, and no secondary changes such as fibrosis or joint stiffness are present yet. " 05/01/2008 - "Although transplantation of AD-CMG or BM-MNC also had a positive, albeit smaller, effect on angiogenesis and fibrosis in the infarcted hearts, this benefit did not translate into a significant improvement in heart function or tissue viability. " 08/01/2005 - "High-dose MP treatment for early subclinical rejection may be effective in suppressing the development of interstitial fibrosis at 1 yr after transplantation." 09/01/2001 - "The prevalence of liver injury increased significantly with time (42% v 56% at 1 and 5 years, respectively; P =.09) and was significantly greater in patients who underwent transplantation for HCV-related cirrhosis than in those who underwent transplantation for other reasons (P =.0001). " 10/15/1998 - "Transarterial chemoembolization may also be effective in patients with advanced cirrhosis and unresectable lesions who are awaiting transplantation. " Order ALL the reference details at left...
3.	Transplants (Transplant) 12/01/2002 - "In one patient the fibrosis resolved completely 180 d post transplant. " 05/01/2000 - "The rate of global obsolescence, and the degree of interstitial fibrosis in post-transplant IgAN were significantly greater than in primary IgAN (P<0.05). " 03/15/1992 - "Wall thickness was significantly greater in the vein grafts after long-term implantation than in the freshly harvested veins (average thickness 1.4 +/- 0.5 vs. 0.7 +/- 0.2 mm, p less than 0.007); this finding correlated histologically with vein wall fibrosis. " 08/01/1990 - "Grafts and donor sites treated with direct current showed more rapid reepithelialization, decreased contraction, improved hair survival, and decreased dermal fibrosis when compared to controls not treated with direct current. " 07/01/1982 - "We conclude that (1) except for significant fibrosis, transplants have normal structure and function after 4, 8, and 12 hours of preservation, (2) in assessing the efficacy of hypothermic cardioplegic preservation, chronic structural changes are more sensitive than functional changes, and (3) hypothermic cardioplegic preservation is feasible up to 12 hours but fibrosis may be the ultimate limiting factor in man." Order ALL the reference details at left...
4.	Sclerotherapy 07/01/1991 - "Sclerotherapy was most effective in patients of (EHO), than (NCPF) followed by cirrhosis of the liver." 11/01/1994 - "Sclerotherapy was not found to improve survival in patients, irrespective of the etiology of cirrhosis (alcoholic or nonalcoholic) or variceal size (low-grade or high-grade). " 01/01/1998 - "The purpose of this multicenter, randomized controlled trial is to compare the efficacy of TIPS with that of endoscopic sclerotherapy in the prevention of variceal rebleeding in cirrhosis. " 12/30/1996 - "The methodology is illustrated using data from 26 clinical trials which investigate the prevention of cirrhosis using beta-blockers and sclerotherapy. " 01/01/1988 - "In our study, we examined the effects of prophylactic sclerotherapy on esophageal motility in 15 patients with Child's A cirrhosis of the liver. " Order ALL the reference details at left...
5.	Aftercare (After-Treatment) 11/01/1984 - "The findings indicate that: some degree of marrow fibrosis is present in about one third of the patients with acute myeloid leukaemia at presentation; effective antileukaemia treatment may result in reversal of marrow fibrosis; and increase in marrow fibre content at diagnosis does not affect haemopoietic regeneration after treatment and achievement of complete remission." 03/01/2000 - "Sixty-four subjects (37%) showed significant improvement in ultrasound parenchyma images after treatment and 51 subjects (54%) showed significant improvement of periportal fibrosis. " 10/01/1997 - "CONCLUSIONS: Parameters of hepatic fibrosis either by ultrasonography or by the 2 biochemical tests showed a significant improvement in 55 patients 1 year after treatment, although some of the indices did not yet return to normal levels." 05/01/2006 - "Four of 20 (20%) patients had improvement in Ishak fibrosis scores after treatment. " 03/01/2005 - "Mean decrement in inflammatory grade was 8 scores (range, 4-10) in patients in whom fibrosis improved, and 2 scores (range, 0-4) in patients in whom fibrosis did not decrease after treatment (P < 0.001). " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Fibrosis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1462 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>